发明名称 Combination of CRF antagonists and 5-HT1B receptor antagonists
摘要 The present invention relates to a pharmaceutical composition for treating, for example, a disorder or condition selected from the group consisting of hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress disorder, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal, preferably a human, comprising (i) a corticotropin releasing factor antagonist or a pharmaceutically acceptable salt thereof, (ii) a 5-HT<SUB>1B </SUB>receptor antagonist or a pharmaceutically acceptable salt thereof, wherein the 5-HT<SUB>1B </SUB>receptor antagonist is selected from the group consisting of (A) a compound of the formula I as described in the specification and (B) a compound of the formula II as described in the specification, and optionally (iii) a pharmaceutically acceptable carrier.
申请公布号 US2005171095(A1) 申请公布日期 2005.08.04
申请号 US20040026782 申请日期 2004.12.31
申请人 PFIZER INC 发明人 HOWARD HARRY R.JR.;CHEN YUHPYNG L.
分类号 A61K31/513;A61K31/519;A61K31/541;A61K45/06;(IPC1-7):A61K31/541 主分类号 A61K31/513
代理机构 代理人
主权项
地址